What are the main functions of olaparib targeted drugs?

Olaparib is a member of the family of inhibitors of PARP (polyadenosine diphosphate ribose polymerase), an enzyme that plays a key role in cells repairing DNA damage. In normal cells, PARP maintains genome stability and prevents canceration by repairing DNA damage. In tumor cells, the function of PARP is used to repair DNA damage caused by chemotherapy or radiotherapy, helping cancer cells escape death and continue to grow. By inhibiting the function of PARP, olaparib makes tumor cells unable to repair their DNA damage, leading to their death. This mechanism is particularly effective for cancer patients carrying BRCA1 or BRCA2 gene mutations.

The main efficacy of olaparib is its excellent efficacy in the treatment of certain types of cancer, especially in patients withBRCA mutations. It is mainly used to treat tumors such as ovarian cancer, breast cancer, prostate cancer and pancreatic cancer. Especially for patients who cannot be controlled by traditional chemotherapy, PARP inhibitors provide a new option. Lynparza prevents cancer cells from effectively repairing their DNA, causing tumor cells to accumulate irreparable genetic damage during their continued division, thereby triggering tumor cell death.

Olaparib has shown significant efficacy in patients carryingBRCA1 or BRCA2 gene mutations. Mutations in the BRCA1 and BRCA2 genes greatly reduce the cells' ability to repair DNA, making these patients more sensitive to PARP inhibitor treatment. Lynparza can further aggravate DNA repair defects by inhibiting the function of PARP, achieving the effect of selectively killing tumor cells.

In addition to genetic mutations, olaparib may also be used to treat cancers that are resistant to traditional chemotherapy drugs or targeted therapies. Particularly in advanced breast, ovarian, and pancreatic cancer, olaparib may be used as maintenance therapy to help slow disease progression.

Reference materials:https://www.lynparza.com/